Document Detail


Molecular abnormalities of the B cell in systemic lupus erythematosus are candidates for functional inhibition treatments.
MedLine Citation:
PMID:  24588739     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Introduction: The B cell is a key player in the pathogenesis of systemic lupus erythematosus (SLE). Loss of B cell tolerance resulting in autoantibody production and immune complex formation and deposition are central features of the disease. B cell overactivity is a hallmark of SLE and molecular abnormalities in B cell signaling cascade have been described. Areas covered: In this review, we will focus on the aberrant phenotype of B cell signaling in patients with lupus. We will also discuss data stemming from the use of small molecules that have recently been recognized to target important steps of the B cell signal transduction pathways with therapeutic implications for SLE. Expert opinion: Attempts to target the B cell in SLE have been made through depletion, blocking of survival factors and co-receptor inhibition. However, the still unmet need for effective therapy of refractory disease makes the necessity for new drugs impelling.
Authors:
Stamatis-Nick C Liossis; Konstantinos Melissaropoulos
Related Documents :
24271829 - Polyamine-dna interactions: possible site of new cancer chemotherapeutic intervention.
24549719 - Lithium chloride decreases proliferation and migration of c6 glioma cells harboring iso...
25086589 - Arrangement of mixed-linkage glucan and glucuronoarabinoxylan in the cell walls of grow...
24434189 - A novel fluorometric assay for aldo-keto reductase 1c3 predicts metabolic activation of...
23575069 - A preliminary study on the radiation-resistance mechanism in ovarian cancer.
22961769 - Microrna-mediated somatic cell reprogramming.
15790899 - Serum deprivation induces apoptotic cell death of transformed rat retinal ganglion cell...
6965099 - Bromodeoxyuridine mutagenesis in mammalian cells is related to deoxyribonucleotide pool...
17374419 - Establishment of a novel small cell lung carcinoma cell line with specific recoverin ex...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-3-4
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  -     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2014 Mar 
Date Detail:
Created Date:  2014-3-4     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  An Isothiourea-catalyzed Asymmetric [2,3]-Rearrangement of Allylic Ammonium Ylides.
Next Document:  Formulation and evaluation of gastroretentive floating drug delivery system of dipyridamole.